Obesity and cardiometabolic disease drive most of it. A healthy 45-year-old participant today becomes a six-figure claim at 55 and the fund pays for what no one managed in between.
GLP-1 medications changed what’s clinically possible, but without a system around them they introduce volatility, not value.
Cardiometabolic disease moves through stages — overweight, obesity, pre-diabetes, type 2 diabetes, cardiovascular disease. Most plans only feel the cost at Stage 4 or 5, when claims are largest and the damage is hardest to undo.
Onsera works upstream. One continuous program — predictive risk modeling, integrated clinical care, behavior change, and disciplined medication management — that catches participants earlier in the progression, and keeps them there.
Onsera is a closed-loop system that turns cardiometabolic spend from a liability into a managed outcome.
Built for speed, access, and measurable outcomes—our guarantees ensure your population gets the care they need, when they need it, with results you can track.
Built so every participant and every covered family member actually uses what the plan pays for. No coordinating between vendors. No surprise bills. No falling through the cracks between visits.
Onsera goes straight to the manufacturers, so the fund gets the best market price on the medications driving its biggest spend. The result is a GLP-1 line item that behaves like a managed program.
Eligibility follows your plan design and applies to participants and dependents meeting clinical criteria: BMI ≥ 30, BMI ≥ 27 with comorbidity, or early cardiometabolic risk.
Better adherence. Lower cost. Measurable outcomes.
